Pesquisas alternativas:
develop type » developing type (Expandir a Pesquisa)
drug lists » drug list (Expandir a Pesquisa), drug costs (Expandir a Pesquisa), drug tests (Expandir a Pesquisa)
a develop » 3 develop (Expandir a Pesquisa), a developed (Expandir a Pesquisa), can develop (Expandir a Pesquisa)
drug loss » drug lots (Expandir a Pesquisa), drug cross (Expandir a Pesquisa), drug loads (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
drug lists » drug list (Expandir a Pesquisa), drug costs (Expandir a Pesquisa), drug tests (Expandir a Pesquisa)
a develop » 3 develop (Expandir a Pesquisa), a developed (Expandir a Pesquisa), can develop (Expandir a Pesquisa)
drug loss » drug lots (Expandir a Pesquisa), drug cross (Expandir a Pesquisa), drug loads (Expandir a Pesquisa)
1
Por Shibata, Annemarie, McMullen, Emily, Pham, Alex, Belshan, Michael, Sanford, Bridget, Zhou, You, Goede, Michael, Date, Abjijit A., Destache, Christopher J.
Publicado em 2013
Assuntos:
“...Preclinical Studies/Drug Development...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Liang, H C, Li, H, McKinnon, R A, Duffy, J J, Potter, S S, Puga, A, Nebert, D W
Publicado em 1996
“... the developmental and metabolic functions of this enzyme, we developed a CYP1A2-deficient mouse line by homologous...”Publicado em 1996
Obter o texto integral
Obter o texto integral
Artigo
3
“... with improved glycemic control and weight loss. Dapagliflozin is most advanced in development of this new drug...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., Schmelmer, V., Amzel, L. M., Freire, E.
Publicado em 2007
“...Drug resistance is a major problem affecting the clinical efficacy of antiretroviral agents...”Publicado em 2007
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por T. V. Romanova, T. M. Bukatina, E. O. Zhuravleva, G. V. Kutekhova, I. I. Snegireva, M. A. Darmostukova, D. A. Kaperko, N. Yu. Velts, A. S. Kazakov, E. V. Shubnikova, R. N. Alyautdin
Publicado em 2018-06-01
Assuntos:
“...type 2 diabetes...”Publicado em 2018-06-01
Obter o texto integral
Artigo
6
Por Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., Prignano, F., Annese, V., Romagnani, S., Maggi, E., Matucci, A.
Publicado no Clin Exp Immunol (2016)
“...Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading...”Publicado no Clin Exp Immunol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Plotkin, Scott R., Halpin, Chris, Blakeley, Jaishri O., Slattery, William H., Welling, D. Bradley, Chang, Susan M., Loeffler, Jay S., Harris, Gordon J., Sorensen, A. Gregory, McKenna, Michael J., Barker, Fred G.
Publicado em 2009
“...Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Wiley, Luke A., Burnight, Erin R., Drack, Arlene V., Banach, Bailey B., Ochoa, Dalyz, Cranston, Cathryn M., Madumba, Robert A., East, Jade S., Mullins, Robert F., Stone, Edwin M., Tucker, Budd A.
Publicado no Hum Gene Ther (2016)
“...-onset, severe central vision loss. Affected children develop seizures and CNS degeneration accompanied...”Publicado no Hum Gene Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
“... patients can induce the development of an HIV-1 RT harboring a dipeptide insertion at the RT fingers domain...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Christopher S. Koivisto, Melodie Parrish, Santosh B. Bonala, Soo Ngoi, Adrian Torres, James Gallagher, Rebekah Sanchez-Hodge, Victor Zeinner, Georges J. Nahhas, Bei Liu, David E. Cohn, Floor J. Backes, Paul J. Goodfellow, Helen M. Chamberlin, Gustavo Leone
Publicado em 2020-10-01
Assuntos:
“...Preclinical drug evaluation...”Publicado em 2020-10-01
Obter o texto integral
Artigo
11
Por Thomas, Sarah K, McDowell, Sarah E, Hodson, James, Nwulu, Ugochi, Howard, Rachel L, Avery, Anthony J, Slee, Ann, Coleman, Jamie J
Publicado em 2013
Assuntos:
“...Drug Safety...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Elisa S. Roesti, Christina N. Boyle, Daniel T. Zeman, Marcos Sande-Melon, Federico Storni, Gustavo Cabral-Miranda, Alexander Knuth, Thomas A. Lutz, Monique Vogel, Martin F. Bachmann
Publicado em 2020-03-01
“...Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by insulin...”Publicado em 2020-03-01
Obter o texto integral
Artigo
13
Por Nabovati, Ehsan, Vakili-Arki, Hasan, Taherzadeh, Zhila, Saberi, Mohammad Reza, Abu-Hanna, Ameen, Eslami, Saeid
Publicado no Res Pharm Sci (2016)
“... relevant potential drug-drug interactions (pDDIs) in a large outpatient population of a developing country...”Publicado no Res Pharm Sci (2016)
Obter o texto integral
Obter o texto integral
Artigo
14
Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions...
Por A. A. Kachanova, Yu. A. Pimenova, G. N. Shuev, K. A. Akmalova, Zh. A. Sozaeva, N. M. Krasnova, E. A. Grishina, D. A. Sychev
Publicado em 2021-03-01
“... adverse drug reactions (ADRs) associated with anti-tuberculosis medicines is hepatotoxicity.The aim...”Publicado em 2021-03-01
Obter o texto integral
Artigo
15
“... from drug development and the importance of individual patient benefits compared to the collective...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
17
18
Por Qi Zhang, Carmen Gonelle-Gispert, Yanjiao Li, Zhen Geng, Zhen Geng, Sandrine Gerber-Lemaire, Yi Wang, Yi Wang, Leo Buhler, Leo Buhler, Leo Buhler
Publicado em 2022-04-01
“...Islet transplantation is a promising approach for the treatment of type 1 diabetes (T1D). Currently...”Publicado em 2022-04-01
Obter o texto integral
Artigo
19
“.... Loss of function mutations in upstream regulators of mTOR have been highly associated with dysplasias...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
“...Type 2 diabetes mellitus (T2DM) is rapidly increasing in prevalence and is a major public health...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo